Nucleai partners with Sirona Dx for AI-driven discovery of biomarkers in solid tumours

pharmafile | July 14, 2022 | News story | Business Services  

Nuclei and Sirona Dx have announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumours.

The partnership combines Nucleai’s AI spatial analytics platform with Sirona Dx’s multiplex assay development expertise, to identify novel spatial signatures in high-plex assays, which predict response to therapy and inform treatment decisions.

Nucleai’s AI-powered spatial biology algorithm supports various image modalities and cancer indications, offering a highly customisable, deployable solution across the drug development ecosystem.

This strategic partnership will enable Sirona Dx to provide Nucleai and its customers with a CRO partner that can allow deployment of AI-based algorithms to support biopharma clinical trials.

“We are delighted to announce a partnership with Nucleai,” said Andrew Brown, PhD, Chief Commercial Officer at Sirona Dx. “Nucleai’s AI-driven analytical capabilities are exceptional. Our combined expertise in multiplexed tissue assay development, data generation and state-of-the-art analysis will unlock new spatial insights and accelerate the spatial biology revolution in precision medicine.”

“Multiplex imaging technologies have improved rapidly over the years; however, identifying actionable insights from all the data collected remains immensely challenging,” says Avi Veidman, co-founder and CEO of Nucleai. “This powerful synergy between Sirona Dx and Nucleai is very exciting, as it will allow us to identify actionable spatial signatures that can predict response to immunotherapy.”


Lina Adams

Related Content

No items found

Latest content